We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition? Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt NO difference in relapse rate at 26, 52 wks despite addition of Anakinra @RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG

VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ

What a result!!! Crowed split 49% against and 51% for MCTD as a unique disease entity Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group Fantastic session from all the presenters @RheumNow #ACR24 https://t.co/GgTVQ1VNWP

Super helpful results from COVER study, holding JAK or IL17 for COVID boosters Antibody titers went up regardless of holding Holding caused flares (14-25% increase!) Pretty clear message; continue JAK / IL17 #ACR24 @RheumNow Abstr#1718 #ACRbest https://t.co/Mf89dWrRWz

Would be helpful for us (and pts) to better understand rimmunotherapy agent specific risk on subsequent GCA/PMR AFTRER propensity matching of >7k pt on combo nivolumab/ipilimumab compared to pembrolizumab: - PMR RR 3.8x N/I vs. P - no diff in GCA risk @RheumNow #ACR24 https://t.co/IF4Gh7Cumd

🔶Clinical Year in Review #ACR24 🔶 Talk By @MHPillingerMD • Review some of the most impactful studies in Rheumatology from the past year! #RheumTwitter #Rheumatology https://t.co/1ULDB2l4gX